It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IMTX’s FA Score shows that 0 FA rating(s) are green whileKNSA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IMTX’s TA Score shows that 4 TA indicator(s) are bullish while KNSA’s TA Score has 3 bullish TA indicator(s).
IMTX (@Biotechnology) experienced а -9.78% price change this week, while KNSA (@Biotechnology) price change was -4.90% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.67%. For the same industry, the average monthly price growth was +16.10%, and the average quarterly price growth was +36.47%.
IMTX is expected to report earnings on Nov 15, 2023.
KNSA is expected to report earnings on Oct 30, 2023.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
|IMTX||KNSA||IMTX / KNSA|
2 days ago69%
2 days ago87%
2 days ago49%
2 days ago82%
2 days ago52%
2 days ago65%
2 days ago84%
2 days ago60%
2 days ago85%
13 days ago77%
9 days ago80%
3 days ago75%
3 days ago83%
2 days ago79%
2 days ago86%
2 days ago55%
A.I.dvisor indicates that over the last year, IMTX has been loosely correlated with FATE. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if IMTX jumps, then FATE could also see price increases.
A.I.dvisor indicates that over the last year, KNSA has been loosely correlated with MDGL. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if KNSA jumps, then MDGL could also see price increases.